Cargando…

Antibody kinetics in primary- and secondary-care physicians with mild to moderate SARS-CoV-2 infection

Three hundred and ninety-seven primary- and secondary-care physicians were tested for the presence of IgG (and IgA) antibodies against SARS-coronavirus-2 with a commercially available ELISA. In 19 of 20 individuals with PCR-proven infection and only mild to moderate symptoms not requiring hospitaliz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orth-Höller, Dorothea, Eigentler, Angelika, Weseslindtner, Lukas, Möst, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473111/ https://www.ncbi.nlm.nih.gov/pubmed/32654611 http://dx.doi.org/10.1080/22221751.2020.1793690

Ejemplares similares

Kinetics of SARS-CoV-2 specific antibodies (IgM, IgA, IgG) in non-hospitalized patients four months following infection
por: Orth-Höller, Dorothea, et al.
Publicado: (2021)

Pooled saliva samples as an approach to reduce the spread of infections with SARS-CoV-2
por: Möst, Johannes, et al.
Publicado: (2021)

Characterization of the antibody response to SARS‐CoV‐2 in a mildly affected pediatric population
por: Kopanja, Sonja, et al.
Publicado: (2022)

Blood lactate in mild and moderate ARDS secondary to SARS COV 2
por: Pagano, A., et al.
Publicado: (2023)

Non-invasive CPAP in mild and moderate ARDS secondary to SARS-CoV-2
por: Pagano, A., et al.
Publicado: (2020)

Breakthrough infections with SARS-CoV-2 omicron efficiently boost antibodies from previous BNT162b2 vaccinations
por: Perkmann, Thomas, et al.
Publicado: (2023)

Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays
por: Weidner, Lisa, et al.
Publicado: (2020)

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
por: Zaqout, Ahmed, et al.
Publicado: (2022)

The kinetics of viral load and antibodies to SARS-CoV-2
por: Sun, Jiufeng, et al.
Publicado: (2020)

Kinetics and seroprevalence of SARS-CoV-2 antibodies in children
por: Roarty, Cathal, et al.
Publicado: (2021)

Inhibition of terminal complement activation in severe Shiga toxin-associated HUS – perfect example for a fast track from bench to bedside
por: Orth-Höller, Dorothea, et al.
Publicado: (2011)

SARS-CoV-2 Antibody Response against Mild-to-Moderate Breakthrough COVID-19 in Home Isolation Setting in Thailand
por: Mongkolsucharitkul, Pichanun, et al.
Publicado: (2022)

Delayed seropositivity is associated with lower levels of SARS-CoV-2 antibody levels in patients with mild to moderate COVID-19
por: Fekry, Marwa M., et al.
Publicado: (2023)

Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays
por: Semmler, Georg, et al.
Publicado: (2021)

Kinetics and seroprevalence of SARS-CoV-2 antibodies: a comparison of 3 different assays
por: Kahre, Elisabeth, et al.
Publicado: (2021)

Screening and Confirmatory Testing for SARS-CoV-2 Antibodies: Comparison of Health and Non-Health Workers in a Nationwide Healthcare Organization in Central Europe
por: Bartko, Johann, et al.
Publicado: (2021)

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19
por: Wheatley, Adam K., et al.
Publicado: (2021)

SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19
por: Glück, Vivian, et al.
Publicado: (2021)

Characterization of 100 sequential SARS‐CoV‐2 convalescent plasma donations
por: Jungbauer, Christof, et al.
Publicado: (2020)

Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2
por: Markewitz, Robert, et al.
Publicado: (2022)

SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year
por: Garner-Spitzer, Erika, et al.
Publicado: (2022)

Assay dependence of long-term kinetics of SARS-CoV-2 antibodies
por: Schallier, Anneleen, et al.
Publicado: (2021)

The Kinetics of SARS-CoV-2 Antibody Development Is Associated with Clearance of RNAemia
por: Wang, Chuangqi, et al.
Publicado: (2022)

Casirivimab-Imdevimab (REGN-COV2) for Mild to Moderate SARS-CoV-2 Infection in Kidney Transplant Recipients
por: Liu, Esther C., et al.
Publicado: (2021)

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
por: Zhang, Lin, et al.
Publicado: (2021)

Dynamics of Antibody Responses after Asymptomatic and Mild to Moderate SARS-CoV-2 Infections: Real-World Data in a Resource-Limited Country
por: Sayabovorn, Naruemit, et al.
Publicado: (2023)

Infection with SARS-CoV-2 Is Associated with Elevated Levels of IP-10, MCP-1, and IL-13 in Sepsis Patients
por: Eichhorn, Tanja, et al.
Publicado: (2023)

Inhaled aprotinin reduces viral load in mild‐to‐moderate inpatients with SARS‐CoV‐2 infection
por: Redondo‐Calvo, Francisco Javier, et al.
Publicado: (2022)

TH-170. Autonomic testing in mild and moderate Sars-Cov-2 patients, single center experience
por: Macias-Gallardo, Julio, et al.
Publicado: (2022)

Post-COVID-19 syndrome symptoms after mild and moderate SARS-CoV-2 infection
por: Al-Husinat, Lou’i, et al.
Publicado: (2022)

SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab
por: Stiasny, Karin, et al.
Publicado: (2022)

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans
por: Vanshylla, Kanika, et al.
Publicado: (2021)

Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination
por: Garcia, Laura, et al.
Publicado: (2022)

KINETICS OF ANTI-SARS-COV-2 IGG ANTIBODIES POST-COVID-19 -VACCINATION
por: Kamal, S., et al.
Publicado: (2023)

Influence of antibiotic treatment on the detection of S. aureus in whole blood following pathogen enrichment
por: Pilecky, Matthias, et al.
Publicado: (2019)

An adolescent with herpes simplex encephalitis, presenting with mild symptoms and rapid deterioration: A case report
por: Stepien, Natalia, et al.
Publicado: (2020)

Antibody Responses One Year after Mild SARS-CoV-2 Infection
por: Choe, Pyoeng Gyun, et al.
Publicado: (2021)

A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital
por: Farcy, David A., et al.
Publicado: (2022)

Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses
por: Ortega, Natalia, et al.
Publicado: (2021)

Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination
por: Graninger, Marianne, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2j75gb2pccrnl227ap1l018kbp